AGEN touts GSK’s RSV data—even though AGEN no longer has an economic stake in the QS-21 adjuvant, as far as I know: https://www.globenewswire.com/news-release/2022/10/13/2533896/8060/en/GSK-s-older-adult-RSV-vaccine-candidate-containing-Agenus-QS-21-STIMULON-shows-94-1-reduction-in-severe-RSV-disease-and-overall-vaccine-efficacy-of-82-6-in-pivotal-trial.html